Cytokine Storm Clinical Trial
Official title:
The Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D Deficiency
Verified date | February 2022 |
Source | Applied Science Private University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The effect of Weekly 50,000 IU vitamin D3 supplements on the serum levels of selected cytokines involved in cytokine storm of Covid-19; A randomized clinical trial in the Covid-19 uninfected people with vitamin D deficiency.
Status | Completed |
Enrollment | 100 |
Est. completion date | April 15, 2021 |
Est. primary completion date | March 22, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 66 Years |
Eligibility | Inclusion Criteria: Age =30 years old Male and female Jordanian ASU students and employees who live in Amman. Informed written consent from the participant prior to the start of the study. a serum 25(OH)D concentration less than 30 ng/mL. Exclusion Criteria: Any eligible subject refuses to apply with informed written consent before the start of the study. Men or women previously diagnosed with chronic diseases, including kidney disease or GIT problems. Who are receiving vitamin D3 supplements (3 months before the start of the study). Pregnant, Breastfeeding females, Females using hormonal contraceptives |
Country | Name | City | State |
---|---|---|---|
Jordan | Mahmoud S Abu-Samak | Amman |
Lead Sponsor | Collaborator |
---|---|
Applied Science Private University |
Jordan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | lipid profile parameters | seum levels | 8 weeks | |
Primary | IL-1 beta | seum levels | 8 weeks | |
Primary | IL-6 | serum levels | 8 weeks | |
Primary | TNF | serum levels | 8 weeks | |
Secondary | serum concentrations of 25-hydroxyvitamin D | ng/ml | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03685383 -
Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation
|
N/A | |
Recruiting |
NCT05491304 -
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
|
Phase 4 | |
Completed |
NCT05307601 -
Immune Response Following COVID-19 in Hemodialysis Patients
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04798677 -
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
|
N/A | |
Completed |
NCT01302223 -
Keratinocyte Growth Factor and Cytokines in Burns.
|
N/A | |
Completed |
NCT04483271 -
The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm
|
N/A | |
Not yet recruiting |
NCT05013034 -
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
|
Phase 2 | |
Completed |
NCT04910893 -
Cytokine Adsorption in Severe, Refractory Septic Shock
|
N/A | |
Completed |
NCT04854252 -
Inflammatory Response to Opioid Versus Opioid Free Anesthesia
|
N/A | |
Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
Terminated |
NCT04415073 -
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
|
Phase 2 | |
Completed |
NCT04377308 -
Fluoxetine to Reduce Intubation and Death After COVID19 Infection
|
Phase 4 | |
Completed |
NCT04324528 -
Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT05476848 -
Relationship Between Oral Findings and Salivary Factors in Sars-Cov-2 Patients
|
N/A | |
Completed |
NCT04913298 -
Prospective Study for the Application of Cytosorb® in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04753476 -
Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
|
Phase 2 | |
Terminated |
NCT04327505 -
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04433078 -
RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
|
Phase 2 | |
Completed |
NCT04901338 -
Cytokine Hemoadsorption in ECMO Patients
|